



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| FILING DATE                  | FIRST NAMED INVENTOR  | ATTORNEY DOCKET NO.  | CONFIRMATION NO.   |
|------------------------------|---|--|--|
| 03/28/1995                   | MICHEL PERRICAUDET  | EX93015G1-US   | 5785   |
| 590 04/10/2006               |   | EXAMINER   |  |
| WILEY, REIN & FIELDING, LLP  |   | PRIEBE, SCOTT DAVID  |  |
| IT ADMINISTRATION<br>ET N.W. |   | ART UNIT   | PAPER NUMBER   |
| N, DC 20006                  |   | 1633   |  |
|                              | 03/28/1995 690 04/10/2006 N & FIELDING, LLP IT ADMINISTRATION ET N.W. | 03/28/1995 MICHEL PERRICAUDET 690 04/10/2006 N & FIELDING, LLP IT ADMINISTRATION ET N.W. | 03/28/1995 MICHEL PERRICAUDET EX93015G1-US  90 04/10/2006 EXAM  N & FIELDING, LLP  IT ADMINISTRATION  ET N.W. ART UNIT |

DATE MAILED: 04/10/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



## UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS P.O. Box 1450

Alexandria, Virginia 22313-1450

| APPLICATION NO./<br>CONTROL NO. | FILING DATE | FIRST NAMED INVENTOR / PATENT IN REEXAMINATION | ATTORNEY DOCKET NO. |
|---------------------------------|-------------|--|---------------------|
|                                 |             |  |                     |

**EXAMINER** 

**ART UNIT** 

PAPER

20060405

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner for Patents** 

The following allowable claim is suggested for the purpose of an interference:

85. A replication defective recombinant adenovirus comprising:

ITR sequences,

an encapsulation sequence, and

a heterologous DNA sequence;

wherein adenoviral genes that are required for replication consisting of E1 and E4 genes have been rendered non-functional, wherein the adenovirus is a human group C adenovirus, and optionally wherein adenoviral E3 genes have been rendered nonfunctional.

The suggested claim must be copied exactly as a new claim or in place of instant claim 45, although other claims may be proposed under 37 CFR 41.202.

Applicant should make the suggested claim in reply to the Office action of 12/23/05. Failure to do so will be considered a disclaimer of the subject matter of this claim under the provisions of 37 CFR 41.202(c).

Claims 45-60, 82, and 83 are considered unpatentable over this suggested claim.

Scott D. Priebe, Ph.D. **Primary Examiner** 

Art Unit: 1633